Filing Flows

Filing Flows › Companies › Pacific Biosciences of California › Report card

Pacific Biosciences of California earnings report card

Every report on file against what analysts and the company itself expected, and what the stock did

Beat rate4 of 5 reports beat the EPS estimate

Pacific Biosciences of California (PACB) beat the analysts' EPS estimate in 4 of its last 5 reports (80%), by +8.1% on average.

Beat rate80% of 5
Average surprise+8.1%

Report by report

QuarterReportedEPS est.EPS reportedSurpriseRevenue reported
Q3 2026Nov 4, 2026−$0.13−$0.11+16.1%$40.6M
Q2 2026Aug 5, 2026−$0.13−$0.14-10.4%$39.0M
Q1 2026May 7, 2026−$0.13−$0.12+8.7%$37.2M
Q4 2025Feb 12, 2026−$0.13−$0.12+10.8%$44.6M
Q3 2025Nov 5, 2025−$0.14−$0.12+15.1%$38.4M

Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. No daily prices are on file for these report days, so the stock's moves are not shown.

Charts

Pacific Biosciences of California: EPS reported against the estimatePacific Biosciences of California: EPS reported against the estimateEstimateReported−$0.14−$0.12Q3 2025−$0.13−$0.12Q4 2025−$0.13−$0.12Q1 2026−$0.13−$0.14Q2 2026−$0.13−$0.11Q3 2026
Latest (Q3 2026): Estimate −$0.13, Reported −$0.11.

The next report: what to expect → Pacific Biosciences of California: every quarter →

Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.